Christina Coughlin appointed chief medical officer

Privately-owned UK biotech company Immunocore has appointed Christina Coughlin as chief medical officer.

She will be responsible for providing medical and regulatory leadership to pre-clinical and clinical programs for the company. Dr Coughlin has experience in oncology drug development, in clinical development and translational medicine, and brings more than 10 years of pharma industry experience. Most recently, she was leading two early development programs at Novartis (NOVN: VX) in checkpoint inhibition and PI3 kinase inhibition.

Eliot Forster, chief executive of Immunocore, said: “I am delighted that Chris has chosen to join Immunocore. She will be working at the heart of our immuno-oncology programs and will be a key member of the senior team. Chris joins Immunocore at a very exciting time as we continue to advance our pipeline of “ImmTACs” for the treatment of cancer. Her experience and background both in clinical development and translational medicine will add significant depth and expertise to our team.”